Compare BIO-TECHNE Corp (TECH) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tesla, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Tesla, Inc. trades at $366.2 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 127.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| TECH | TSLA | |
|---|---|---|
Market Cap | $11.34B | $1.45T |
Sector | Health | Consumer Cyclical |
52-Week High | $72.48 | $489.88 |
52-Week Low | $43.31 | $298.16 |
Enterprise Value | $11.36B | $1.43T |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Tesla (TSLA) trades at $368.16, up 3.98% in the last 24 hours, with a bullish technical signal from moving averages and ADX indicators. Recent earnings show a mix of beats and a miss, with Q2 2026 EPS of $0.33 falling short of the $0.50 estimate. The company's revenue declined to $94.83 billion in 2025, and net income margin compressed to 3.67%, while valuation ratios like P/E of 340.89 remain elevated. Positive news includes regulatory approval for self-driving software in Europe and a surge in German registrations.
Tesla's outlook hinges on execution in autonomous driving and energy segments, but high valuation and margin pressures pose risks. Analyst consensus is mixed with a $398.38 price target, suggesting moderate upside, though competition and demand volatility require caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
